<code id='8583859695'></code><style id='8583859695'></style>
    • <acronym id='8583859695'></acronym>
      <center id='8583859695'><center id='8583859695'><tfoot id='8583859695'></tfoot></center><abbr id='8583859695'><dir id='8583859695'><tfoot id='8583859695'></tfoot><noframes id='8583859695'>

    • <optgroup id='8583859695'><strike id='8583859695'><sup id='8583859695'></sup></strike><code id='8583859695'></code></optgroup>
        1. <b id='8583859695'><label id='8583859695'><select id='8583859695'><dt id='8583859695'><span id='8583859695'></span></dt></select></label></b><u id='8583859695'></u>
          <i id='8583859695'><strike id='8583859695'><tt id='8583859695'><pre id='8583859695'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:3931

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In